Multiple studies have been conducted to evaluate the performance of oral semaglutide, which is the first oral medication in the glucagon-like peptide-1 (GLP-1) receptor agonist drug class. The PIONEER 8 trial found reductions in A1c and body weight when oral semaglutide is paired with various insulin regimens. Read more